Organ Transplantation
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 programPerceived Barriers to Patient Adherence After Pediatric Solid Organ TransplantationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsPerceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation
Clinical Trials (2)
Total enrollment: 502 patients across 2 trials
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
N/ANo Longer Available
NCT01370746Allergy TherapeuticsPerceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation
Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation
Start: Apr 2012Est. completion: Apr 2014502 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.